Copyright
©The Author(s) 2019.
World J Gastroenterol. May 21, 2019; 25(19): 2365-2372
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2365
Published online May 21, 2019. doi: 10.3748/wjg.v25.i19.2365
Variables | All (n = 20) |
Age, yr | 68.6 ± 8.4 |
Gender, male : female | 19:1 |
BMI, kg/m2 | 22.2 ± 4.2 |
ECOG PS, 0:1: | 18:2 |
Etiology, HBV:HCV:alcohol:others | 7:7:3:3 |
AST, IU/L | 52.2 ± 38.1 |
ALT, IU/L | 45.1 ± 26.3 |
T.Bil, mg/dL | 0.7 ± 0.4 |
Alb, g/dL | 3.4 ± 0.5 |
PT, % | 82.2 ± 15.2 |
Plt, × 104/μL | 19.7 ± 6.1 |
Child–Pugh score, 5:6 points | 8:12 |
Median AFP, ng/mL (range) | 268 (4.5-53000) |
Intrahepatic tumor size, cm | 6.6 ± 6.3 |
Number of intrahepatic tumors, single : multiple | 3:17 |
Portal vein invasion, n (%) | 9 (45.0) |
Extrahepatic metastasis, n (%) | 15 (75.0) |
Previous treatment, n (%) | 19 (95.0) |
Initial dose of lenvatinib, 8:12 mg/d | 16:4 |
- Citation: Kuorda H, Abe T, Fujiwara Y, Okamoto T, Yonezawa M, Sato H, Endo K, Oikawa T, Sawara K, Takikawa Y. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2019; 25(19): 2365-2372
- URL: https://www.wjgnet.com/1007-9327/full/v25/i19/2365.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i19.2365